CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

On Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name ...

The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...

Opens in a new tab or window The FDA approved esketamine (Spravato) nasal spray as monotherapy for adults with treatment-resistant depression who had an inadequate response to at least two oral ...

Esketamine (Spravato; Johnson & Johnson) is now the first and only monotherapy for adults with major depressive disorder (MDD) with inadequate response to at least 2 oral antidepressants.

Share on Pinterest The FDA has approved an esketamine nasal spray for the treatment of depression cases that do not respond to other therapeutic approaches. Image credit: Koldunov/Getty Images.

Johnson & Johnson is to press on with filings for its new depression drug, esketamine, despite one of two late-stage studies missing an efficacy target. Ketamine is best known as an anaesthetic ...

MDD has a high economic burden, with nearly half of it attributable to treatment-resistant depression (TRD). 3,4,5 "Treatment-resistant depression can be very complicated, especially for patients ...

“This trial of esketamine was one of the pivotal trials in the FDA’s review of this treatment for patients with treatment-resistant depression. Not only was adjunctive esketamine therapy ...

This decision expands the indication of esketamine, offering new hope for patients with treatment-resistant depression(1 Trusted Source FDA approves new nasal spray medication for treatment ...